Advances in Movement Disorders: The 10th Annual NYC Movement Disorder CME Symposium

Sunday, May 23, 2021, 8:00 AM - 4:35 PM


This full-day virtual symposium provides clinicians in the tri-state community with a comprehensive review of cutting-edge practices in the diagnosis, genetics, and management of movement disorders. A broad spectrum of diseases including Parkinson disease, tremor, dystonia, and ataxia will be addressed. Through didactic lecture, video review, and interactive breakout sessions with expert clinicians, attendees will learn about current medical and cutting-edge diagnostic and management strategies including chemodenervation and deep brain stimulation (DBS).

1. Recognize the clinical presentations (abnormal movements) that characterize movement disorders.
2. Devise an appropriate diagnostic and management strategy for the patient with Parkinson disease.
3. Describe an appropriate movement disorder candidate for DBS (deep brain stimulation) surgical intervention.
4. Describe the assessment and management strategy for a patient with ataxia.
5. Discuss current treatment approaches to dystonia including local injections of botulinum toxin and deep brain stimulation (DBS).
6. Discuss the new essential tremor classification system and treatment options for essential tremor, including deep brain stimulation and magnetic resonance imaging guided high intensity focused ultrasound.

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (6.75 hours), Non-Physician Attendance (6.75 hours)

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Sunday, May 23, 2021